Rallybio Corporation (NASDAQ:RLYB – Get Free Report) major shareholder Adar1 Capital Management, Llc bought 50,000 shares of Rallybio stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $14.00 per share, for a total transaction of $700,000.00. Following the completion of the acquisition, the insider owned 829,784 shares in the company, valued at approximately $11,616,976. The trade was a 6.41% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Adar1 Capital Management, Llc also recently made the following trade(s):
- On Tuesday, May 12th, Adar1 Capital Management, Llc bought 800 shares of Rallybio stock. The stock was acquired at an average price of $13.83 per share, for a total transaction of $11,064.00.
- On Tuesday, May 5th, Adar1 Capital Management, Llc bought 35,101 shares of Rallybio stock. The stock was acquired at an average price of $14.00 per share, for a total transaction of $491,414.00.
- On Monday, May 4th, Adar1 Capital Management, Llc bought 120,804 shares of Rallybio stock. The stock was acquired at an average price of $13.97 per share, for a total transaction of $1,687,631.88.
Rallybio Price Performance
Shares of Rallybio stock traded up $0.32 during trading hours on Wednesday, reaching $14.35. The company’s stock had a trading volume of 150,607 shares, compared to its average volume of 633,223. The firm has a 50 day moving average price of $9.70 and a 200-day moving average price of $6.93. Rallybio Corporation has a one year low of $2.16 and a one year high of $15.31. The stock has a market cap of $75.91 million, a P/E ratio of -5.61 and a beta of -1.10.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on RLYB shares. Wall Street Zen upgraded shares of Rallybio to a “hold” rating in a report on Saturday, March 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Rallybio in a report on Friday, May 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
Check Out Our Latest Stock Analysis on Rallybio
Hedge Funds Weigh In On Rallybio
Hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd grew its holdings in Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after purchasing an additional 38,205 shares during the last quarter. Susquehanna International Group LLP grew its holdings in Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after purchasing an additional 113,031 shares during the last quarter. Geode Capital Management LLC boosted its position in Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after buying an additional 2,996 shares during the period. Citadel Advisors LLC boosted its position in Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after buying an additional 373,821 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after buying an additional 120,892 shares during the period. 90.34% of the stock is currently owned by institutional investors.
Rallybio Company Profile
Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.
Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.
Featured Stories
- Five stocks we like better than Rallybio
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.
